On October 30, 2024 Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, reported that a late-breaking abstract featuring the IGNYTE clinical trial primary analysis has been selected for oral presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (SITC 2024) being held November 6-10, 2024, in Houston, Texas (Press release, Replimune, OCT 30, 2024, View Source [SID1234647544]). Data from the ARTACUS clinical trial of RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies will also be shared in an encore poster presentation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Title: Primary analysis of the registration-intended cohort of patients with anti-PD1 failed melanoma from the IGNYTE trial of RP1 plus nivolumab, including clinical subgroup and initial biomarker data
Abstract Number: 1504
Presentation Session Title: Session 204 – Clinical Late-Breaking Abstract Session
Date and Time: Saturday, November 9, 2024, 11:45 am – 12:45 pm CST
Presenter: Michael K. Wong, MD, PhD, University of Texas MD Anderson Cancer Center
Title: Safety and efficacy results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)
Abstract Number: 693
Date and Time: Friday, November 8, 2024
Presenter: Diwakar Davar, MD, UPMC Hillman Cancer Center